Compuen (CGEN) Bɛn Dɛŋɛn Akɔc
AI forecast: CGEN
AI ekek aŋok wɛlɛɛl bɛn bɛn lɔŋɔŋ, bɛn bɛn cɔlɔŋ, kɛ bɛn bɛn cɔlɔŋ. Cɔkɔkɔkɔ cɔlɔŋ bɛn bɛn lɔŋɔŋ. Aŋok wɛlɛɛl aŋok wɛlɛɛl, aŋok wɛlɛɛl aŋok wɛlɛɛl.
Bɛn cɔk ɛcɔk 6
Premium shows the AI's price targets for 1 day, 1 week and 1 month for this and every other stock.
Unlock Premium🔒 Nyɛn cɔk aya bɛn
Ditëëk ë bɛ̈ɛ̈r ë cë lɔ – ditëëk ë cë lɔ kee aköl aköl ë bɛ̈ɛ̈r ë cë lɔ – aye Premium.
Unlock PremiumBɛn kɔc ke bɛn
Compugen Ltd. is engaged in the research, development, and distribution of targeted and therapeutic drugs. The company’s portfolio primarily consists of early-stage and preclinical immuno-oncology programs aimed at developing cancer immunotherapies, both as monotherapies and in combination with other drugs. The company is also developing treatments for autoimmune diseases.